{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Relapse in first 100 days"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Relapse between day 101 to 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Relapse between 6 months to 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Relapse between 1 to 5 years"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Total relapse in first 5 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Relapse defined by the presence of malignant cells in marrow, peripheral blood, or extramedullary sites by histopathology","groups":[{"description":"All participants in single arm study received CD45RA+ T cell depletion PBSC transplant and IV Methotrexate and tacrolimus for GVHD prophylaxis","id":"OG000","title":"Overall Study Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Relapse Post-transplant","type":"SECONDARY","unitOfMeasure":"Participants"}